Results 141 to 150 of about 268,104 (311)
LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1
Advanced Science, EarlyView.LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li +12 more
wiley +1 more source
Indian Journal of OphthalmologyThe emergence of anti-vascular endothelial growth factor (anti-VEGF) therapy has marked a paradigm shift in the treatment of retinal and choroidal vascular diseases.
Chitaranjan Mishra +4 more
doaj +1 more source
Advanced Science, EarlyView.Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong +6 more
wiley +1 more source
Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy
Advanced Science, EarlyView.Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong +5 more
wiley +1 more source
Advanced Science, EarlyView.This study presents the de novo design and directed evolution of a mirror‐image D‐protein inhibitor targeting human interleukin‐4 (IL‐4). The engineered molecule exhibits nanomolar binding affinity for IL‐4 and effectively inhibits IL‐4–mediated signaling.
Liqing Xu +7 more
wiley +1 more source
Advanced Science, EarlyView.Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley +1 more source
Advanced Science, EarlyView.The functional schematic diagram of tumor associated neutrophils. Abstract Enhancing cervical cancer (CC) immunotherapy requires deciphering the heterogeneous tumor immune microenvironment (TIME), particularly neutrophil phenotypic dynamics. Here, 1) we collected 543 CC cases to find that patients with elevated neutrophil levels have a higher incidence
Xingyu Chang +7 more
wiley +1 more source
Sphingomonas paucimobilis‐Driven Epithelial–Endothelial Transition in Adenomyosis Pathogenesis
Advanced Science, EarlyView.This study identifies epithelial–endothelial transition (EET) as a novel adenomyosis pathogenic mechanism driven by Sphingomonas paucimobilis colonization. Systematic inhibitor experiments validate a TNFα→NF‐κB→MMP signaling cascade essential for EET. Critically, bacterial culture supernatant fails to induce pathological changes, demonstrating viable ...
Peigen Chen +7 more
wiley +1 more source
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Advanced Science, EarlyView.Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu +11 more
wiley +1 more source